Drug Type Small molecule drug |
Synonyms Malol, Prunol, Urson + [2] |
Target |
Action inhibitors |
Mechanism Enzymes inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC30H48O3 |
InChIKeyWCGUUGGRBIKTOS-GPOJBZKASA-N |
CAS Registry77-52-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ursolic Acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic Syndrome | Phase 2 | Mexico | 01 Sep 2014 | |
Castration-Resistant Prostatic Cancer | Preclinical | United States | 28 Apr 2025 |
Phase 2 | 10 | Strength Training+Ursolic Acid (UA and Exercise in Paraplegia Group) | fybssedisz(deautblalq) = sagjjxhmrv gwakuwmpkz (stjkisqpwb, 2642.65) View more | - | 21 May 2025 | ||
(UA in Tetraplegia Group) | fybssedisz(deautblalq) = czxuureqik gwakuwmpkz (stjkisqpwb, 1885.21) View more | ||||||
Not Applicable | - | vtewdznfpm(rbevfzkxct) = yovplhpvlw zckvbmaeui (iqonxiowrh ) View more | Positive | 15 Oct 2022 | |||
Phase 2/3 | - | (UA supplementation) | kscxzwphqu(mvhzqnekgl) = nffudvgosy lyqxdzwfpe (ezhryaljwa ) | Negative | 01 Aug 2021 | ||
(Placebo supplementation) | - | ||||||
Phase 2 | 24 | (Ursolic Acid) | sfellwcuey(dohxmircdx) = naucnlicsz bazjojxydp (mkdfzznsjp, 1.2) View more | - | 08 Oct 2020 | ||
Placebo (Placebo) | sfellwcuey(dohxmircdx) = keuekxcrzq bazjojxydp (mkdfzznsjp, 1.4) View more | ||||||
Not Applicable | - | siddtiuewk(gwntvkfipm) = ymqbxthjnu duihlrajwj (dsxrvsjhqx ) | - | 01 Jul 2017 | |||
Not Applicable | - | Ursolic acid (UA) | jzqfyrstpn(zqgqkdxlgg) = the mRNA expression of markers associated with B cell activation (Bcl-6), plasma cell differentiation (Blimp-1) and isotype switching (activation-induced deaminase) was markedly reduced with UA treatment ffidysocse (xkvgomlkuq ) View more | - | 11 Jun 2014 |